<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01007032</url>
  </required_header>
  <id_info>
    <org_study_id>13905</org_study_id>
    <secondary_id>21-1258</secondary_id>
    <secondary_id>CP13-0813</secondary_id>
    <secondary_id>I5A-IE-JAEA</secondary_id>
    <nct_id>NCT01007032</nct_id>
  </id_info>
  <brief_title>A Study of IMC-A12 in Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1 Study Evaluating the Safety and Pharmacokinetic Profiles of IMC-A12 Administered Every 2 Weeks or Every 3 Weeks to Japanese Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medidata Solutions</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, participants will initially receive intravenous (IV) cixutumumab (IMC-A12)
      every 2 weeks or every 3 weeks for 6 weeks (one cycle). After the first cycle, participants
      experiencing a best overall response of complete response, partial response, or stable
      disease will continue to receive cixutumumab at their cohort dose and schedule until there is
      evidence of progressive disease (PD), or until other withdrawal criteria are met.
      Participants will be enrolled at one study center, located in the National Cancer Center
      Hospital - East, Kashiwa, Japan. Approximately 20-30 participants are anticipated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants in this single-center, open-label, dose-escalation, Phase 1 study will initially
      receive intravenous (IV) cixutumumab every 2 weeks or every 3 weeks for 6 weeks (one cycle).
      After the first cycle, participants experiencing a best overall response of complete response
      (CR), partial response (PR), or stable disease (SD) will continue to receive cixutumumab at
      their cohort dose and schedule until there is evidence of progressive disease (PD), or until
      other withdrawal criteria are met.

      A minimum of three participants will be enrolled in each cohort. The starting dose in Cohort
      1 will be 6 mg/kg, administered every 2 weeks. Dose escalation from Cohort 1 to Cohort 2 (10
      mg/kg administered every 2 weeks) will occur once at least three participants in Cohort 1
      have completed one cycle of therapy (ie, completed the initial 6 week treatment period or
      discontinued therapy due to an cixutumumab - related adverse event [AE]).

      Enrollment into Cohort 3 (starting dose: 15 mg/kg administered every 3 weeks) will not
      proceed until all participants have completed one cycle of therapy (as defined above) in
      Cohort 2. Similarly, participants will be enrolled in Cohort 4 once at least three
      participants have completed one cycle of therapy in Cohort 3;participants in Cohort 4 will
      receive 20 mg/kg administered every 3 weeks. Toxicity data for each cohort will be reviewed
      prior to any dose escalation. No intrapatient dose escalation is permitted. Participants in
      any cohort who do not complete the first 6 weeks of treatment for reasons other than an
      cixutumumab-related toxicity will be replaced.

      A dose-limiting toxicity (DLT) is defined as one of the following events, if considered by
      the investigator to be definitely, probably, or possibly related to cixutumumab: Grade 4
      neutropenia lasting &gt; 7 days; Grade 4 anemia; Grade ≥ 3 thrombocytopenia; Grade ≥ 3
      neutropenia associated with fever; Grade 3 or 4 nonhematologic toxicity, excluding
      electrolyte abnormality and Grade 3 hyperglycemia; Grade 4 hyperglycemia; and/or Grade 4 or
      uncontrollable hypertension.

      If three participants complete the first 6-week cycle (according to the definition outlined
      above) with no DLTs, dose escalation to Cohort 2 may proceed. If one DLT is observed in the
      initial three participants of Cohort 1 (or any cohort) during Cycle 1, three additional
      participants will be enrolled into that cohort. If no additional DLTs are observed, dose
      escalation may continue as described above.

      If two or more participants in Cohort 1 experience a DLT, six participants will be enrolled
      into Cohort 1A (receiving 4 mg/kg every 2 weeks). If two or more participants experience a
      DLT in dose Cohort 3, six participants will be enrolled into dose Cohort 3A (10 mg/kg every 3
      weeks). If two or more participants experience a DLT in dose Cohorts 2 or 4, six additional
      participants will be enrolled into the previous cohort (Cohort 1 or Cohort 3, respectively),
      and the previous cohort will be considered the maximum tolerated dose for that dosing
      schedule. If two or more participants in any cohort experience a DLT on Week 7 or beyond
      (after Cycle 1), the data will be reviewed and enrollment may be suspended. The Sponsor and
      Principal Investigator, with reference to the review of the Independent Data Safety
      Evaluation Committee (established in a separate document), will determine whether enrollment
      should resume.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Summary Listing of Percentage of Participants Reporting Treatment-Emergent Adverse Events</measure>
    <time_frame>Up To 63 Months</time_frame>
    <description>A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With a Dose Limiting Toxicity (DLT)</measure>
    <time_frame>First Dose Up to 6 Weeks</time_frame>
    <description>DLTs were defined as any cixutumumab-related Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE 3.0) Grade 3 or 4 adverse events (reported in the subsequent Primary Outcome Measure).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Concentration (Cmax)</measure>
    <time_frame>Prior to Infusion and Immediately Following End of Infusion (Cohorts 1 and 2) at 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 264 and 336 hours and (Cohorts 3 and 4) at 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 264, 336, 408 and 504 Hours Following End of Infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Area Under the Curve From Zero to Infinity AUC(0-∞)</measure>
    <time_frame>Prior to Infusion and Immediately Following End of Infusion (Cohorts 1 and 2) at 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 264 and 336 hours and (Cohorts 3 and 4) at 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 264, 336, 408 and 504 Hours Following End of Infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Area Under Concentration Versus Time Curve During One Dosing Interval (AUCtau)</measure>
    <time_frame>Prior to Infusion and Immediately Following End of Infusion (Cohorts 1 and 2) at 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 264 and 336 hours and (Cohorts 3 and 4) at 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 264, 336, 408 and 504 Hours Following End of Infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life (t1/2)</measure>
    <time_frame>Prior to Infusion and Immediately Following End of Infusion (Cohorts 1 and 2) at 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 264, and 336 hours and (Cohorts 3 and 4) at 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 264, 336, 408 and 504 hours) Following End of Infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug Clearance (CL)</measure>
    <time_frame>Prior to Infusion and Immediately Following End of Infusion (Cohorts 1 and 2) at 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 264, and 336 hours and (Cohorts 3 and 4) at 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 264, 336, 408 and 504 hours) Following End of Infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serum Anti-Cixutumumab Antibody Assessment Immunogenicity</measure>
    <time_frame>6 months</time_frame>
    <description>No participants were analyzed for the development of circulating positive anti-cixutumumab antibodies due to no assay available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])</measure>
    <time_frame>From the First Dose up to 32 Months</time_frame>
    <description>Response defined per Response Evaluation Criteria In Solid Tumors (RECIST 1.1) criteria: Complete Response (CR)=disappearance of all target lesions; Partial Response (PR)=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Tumors</condition>
  <arm_group>
    <arm_group_label>Cixutumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive IV cixutumumab every 2 or 3 weeks. A cycle equals 6 weeks, with radiological evaluation of tumor response after each cycle. After 1st cycle, pts with a complete response (CR), PR, or SD continue to receive cixutumumab cohort dose and schedule disease progression. 3 pts enroll in each cohort. Starting dose in Cohort 1 is 6 mg/kg every 2 weeks. Dose escalation from Cohort 1 to Cohort 2 (10 mg/kg every 2 weeks) occurs at least 3 pts in Cohort 1 completes 1 cycle of therapy. Enrollment into Cohort 3 (starting dose: 15 mg/kg administered every 3 weeks) will not proceed until at least 3 pts have completed one cycle of therapy in Cohort 2. Pts enroll in Cohort 4 once at least 3 pts have completed once cycle of therapy in Cohort 3; pts in Cohort 4 receive 20 mg/kg every 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cixutumumab</intervention_name>
    <description>Cixutumumab intravenously</description>
    <arm_group_label>Cixutumumab</arm_group_label>
    <other_name>IMC-A12</other_name>
    <other_name>LY3012217</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Solid tumor participant who has been histopathologically or cytologically documented

          -  Advanced primary or recurrent solid tumor participant who has not responded to
             standard therapy or for whom no standard therapy is available

          -  The participant has measurable or nonmeasurable lesions according to Response
             Evaluation Criteria in Solid Tumors (RECIST Version 1.0) guidelines

          -  The participant has an Eastern Cooperative Oncology Group performance status (ECOG
             PS)score of 0-1 at study entry

          -  The participant is able to provide informed consent

          -  The participant is age 20 years or older

          -  The participant has a life expectancy of &gt; 3 months

          -  The participant has adequate hematologic function, as defined by:

          -  An absolute neutrophil count (ANC) ≥ 1500/m3 or /μL

          -  A hemoglobin ≥ 10 g/dL; and

          -  A platelet count ≥ 100,000/mm3 or /μL

          -  The participant has adequate hepatic function, as defined by:

          -  Total bilirubin ≤ 1.8 mg/dL

          -  Aspartate transaminase (AST) ≤ 2.5 times the upper limit of site-specific normal
             ranges (five times in case of liver metastasis)

          -  Alanine transaminase (ALT) ≤ 2.5 times the upper limit of site-specific normal ranges
             (five times in case of liver metastasis)

          -  The participant has adequate renal function, as defined by:

          -  Serum creatinine ≤ 1.5 mg/dL

          -  Calculated serum creatinine clearance (Cockcroft-Gault) ≥ 60 mL/min

          -  The participant has fasting blood sugar &lt; 120 mg/dL or below the institutional upper
             limit of normal (ULN) before study entry (one retest of an elevated level is permitted
             at the discretion of the investigator)

          -  The participant has adequate coagulation function, as defined by an international
             normalized ratio (INR) ¬ 1.5

          -  The participant agrees to use adequate contraception for the duration of study
             participation and for 12 weeks after the last dose of study therapy.

          -  The participant has adequate recovery from recent surgery, chemotherapy, and radiation
             therapy (including palliative radiation therapy). At least 28 days (6 weeks for
             nitrosoureas or mitomycin C) must have elapsed from major surgery, prior chemotherapy,
             prior treatment with an investigational agent or device, or prior radiation therapy.
             For treatment with unapproved monoclonal antibodies, a minimum of 8 weeks must have
             elapsed

          -  The participant is willing to comply with study procedures until the end of therapy

        Exclusion Criteria:

          -  The participant has received chemotherapy or therapeutic radiotherapy within 28 days
             (6 weeks for nitrosoureas or mitomycin C) prior to entering the study, or the
             participant has ongoing side effects ≥ Grade 2 due to agents administered more than 28
             days earlier

          -  The participant has undergone major surgery (eg,laparotomy, thoracotomy,removal of
             organ(s)) within 28 days prior to study entry, or subcutaneous venous access device
             placement within 7 days prior to study entry

          -  The participant has elective or planned surgery to be conducted during the trial

          -  The participant has documented and/or symptomatic brain or leptomeningeal metastases
             (participants who are clinically stable (no symptoms during the 4 weeks prior to
             enrollment) with an assessment that no further treatment (radiation, surgical
             excision, or administration of steroids) is required are permitted to enter the study)

          -  The participant has an uncontrolled intercurrent illness including, but not limited
             to:

          -  Thrombotic or hemorrhagic disorders

          -  Gross hemoptysis (approximately one-half a teaspoon)

          -  Ongoing or active infection requiring systemic antibiotic treatment

          -  Congestive heart failure (Class III or IV per the New York Heart Association
             classification for heart disease)

          -  Angina pectoris, angioplasty, stenting, or myocardial infarction within 6 months

          -  Uncontrolled hypertension (systolic blood pressure &gt; 150 mm Hg, diastolic blood
             pressure &gt; 95 mm Hg)

          -  Cardiac arrhythmia requiring treatment (NCICTCAE Version 3.0 Grade 3), or asymptomatic
             sustained ventricular tachycardia

          -  Peripheral neuropathy of any etiology ≥ Grade 2 (NCI-CTCAE Version 3.0); or

          -  Any other serious uncontrolled medical disorder(s) in the opinion of the investigator

          -  The participant has a serious or nonhealing wound, ulcer, or bone fracture within 28
             days prior to study entry

          -  The participant has experienced any Grade 3/4 gastrointestinal bleeding within 3
             months prior to study entry

          -  The participant has participated in clinical studies of unapproved experimental agents
             or procedures within 4 weeks prior to study entry for small molecules, or 8 weeks
             prior to study entry for unapproved monoclonal antibodies

          -  The participant has received any previous treatment with agents targeting the
             insulin-like growth factor hormone (IGF-IR), approved or unapproved

          -  The participant has a known allergy to any of the treatment components (monoclonal
             antibodies or other therapeutic proteins such as fresh frozen plasma, human serum
             albumin, cytokines, or interleukins). In the event that there is suspicion the
             participant may have allergies, the participant should be excluded

          -  The participant, if female, is pregnant (confirmed by urine or serum pregnancy test)
             or lactating

          -  The participant has a known alcohol or drug dependency

          -  The participant is Hepatitis B Virus (HBV) antigen-, Hepatitis C Virus (HCV)
             antibody-, or HIV antibody-positive (asymptomatic healthy carriers with detectable
             HBV-DNA, HCV-RNA may be enrolled into the trial)

          -  The participant is assessed as inadequate for the study by the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ImClone Investigational Site</name>
      <address>
        <city>Kashiwa</city>
        <zip>277 8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>November 2, 2009</study_first_submitted>
  <study_first_submitted_qc>November 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2009</study_first_posted>
  <results_first_submitted>March 17, 2018</results_first_submitted>
  <results_first_submitted_qc>October 19, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 27, 2019</results_first_posted>
  <last_update_submitted>October 19, 2018</last_update_submitted>
  <last_update_submitted_qc>October 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anti-IGF-IR</keyword>
  <keyword>monoclonal</keyword>
  <keyword>solid tumor</keyword>
  <keyword>insulin-like growth factor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants who had progressive disease (PD) were considered to complete the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cixutumumab Cohort 1</title>
          <description>6 milligrams/kilograms (mg/kg) of cixutumumab was administered intravenously (IV) every 2 weeks for 6 weeks (one cycle).</description>
        </group>
        <group group_id="P2">
          <title>Cixutumumab Cohort 2</title>
          <description>10 mg/kg of cixutumumab was administered IV every 2 weeks for 6 weeks (one cycle).</description>
        </group>
        <group group_id="P3">
          <title>Cixutumumab Cohort 3</title>
          <description>15 mg/kg of cixutumumab was administered IV every 3 weeks for 6 weeks (one cycle).</description>
        </group>
        <group group_id="P4">
          <title>Cixutumumab Cohort 4</title>
          <description>20 mg/kg of cixutumumab was administered IV every 3 weeks for 6 weeks (one cycle).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>On Study Treatment at Cut-off Date</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cixutumumab Cohort 1</title>
          <description>6 mg/kg of cixutumumab was administered IV every 2 weeks for 6 weeks (one cycle).</description>
        </group>
        <group group_id="B2">
          <title>Cixutumumab Cohort 2</title>
          <description>10 mg/kg of cixutumumab was administered IV every 2 weeks for 6 weeks (one cycle).</description>
        </group>
        <group group_id="B3">
          <title>Cixutumumab Cohort 3</title>
          <description>15 mg/kg of cixutumumab was administered IV every 3 weeks for 6 weeks (one cycle).</description>
        </group>
        <group group_id="B4">
          <title>Cixutumumab Cohort 4</title>
          <description>20 mg/kg of cixutumumab was administered IV every 3 weeks for 6 weeks (one cycle).</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="7"/>
            <count group_id="B5" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.3" spread="9.52"/>
                    <measurement group_id="B2" value="60.5" spread="6.82"/>
                    <measurement group_id="B3" value="62.2" spread="5.57"/>
                    <measurement group_id="B4" value="60.3" spread="8.67"/>
                    <measurement group_id="B5" value="60.9" spread="7.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Summary Listing of Percentage of Participants Reporting Treatment-Emergent Adverse Events</title>
        <description>A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section.</description>
        <time_frame>Up To 63 Months</time_frame>
        <population>All participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cixutumumab Cohort 1</title>
            <description>6 mg/kg of cixutumumab was administered intravenously (IV) every 2 weeks for 6 weeks (one cycle).</description>
          </group>
          <group group_id="O2">
            <title>Cixutumumab Cohort 2</title>
            <description>10 mg/kg of cixutumumab was administered IV every 2 weeks for 6 weeks (one cycle).</description>
          </group>
          <group group_id="O3">
            <title>Cixutumumab Cohort 3</title>
            <description>15 mg/kg of cixutumumab was administered IV every 3 weeks for 6 weeks (one cycle).</description>
          </group>
          <group group_id="O4">
            <title>Cixutumumab Cohort 4</title>
            <description>20 mg/kg of cixutumumab was administered IV every 3 weeks for 6 weeks (one cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Summary Listing of Percentage of Participants Reporting Treatment-Emergent Adverse Events</title>
          <description>A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section.</description>
          <population>All participants who received at least 1 dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="85.7"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="85.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Dose Limiting Toxicity (DLT)</title>
        <description>DLTs were defined as any cixutumumab-related Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE 3.0) Grade 3 or 4 adverse events (reported in the subsequent Primary Outcome Measure).</description>
        <time_frame>First Dose Up to 6 Weeks</time_frame>
        <population>All participants who completed the first cycle of 6 weeks or discontinued due to Dose Limiting Toxicities (DLTs).</population>
        <group_list>
          <group group_id="O1">
            <title>Cixutumumab 6 mg/kg</title>
            <description>6 mg/kg of cixutumumab was administered intravenously (IV) every 2 weeks for 6 weeks (one cycle).</description>
          </group>
          <group group_id="O2">
            <title>Cixutumumab 10 mg/kg</title>
            <description>10 mg/kg of cixutumumab was administered IV every 2 weeks for 6 weeks (one cycle).</description>
          </group>
          <group group_id="O3">
            <title>Cixutumumab 15 mg/kg</title>
            <description>15 mg/kg of cixutumumab was administered IV every 3 weeks for 6 weeks (one cycle).</description>
          </group>
          <group group_id="O4">
            <title>Cixutumumab 20 mg/kg</title>
            <description>20 mg/kg of cixutumumab was administered IV every 3 weeks for 6 weeks (one cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Dose Limiting Toxicity (DLT)</title>
          <description>DLTs were defined as any cixutumumab-related Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE 3.0) Grade 3 or 4 adverse events (reported in the subsequent Primary Outcome Measure).</description>
          <population>All participants who completed the first cycle of 6 weeks or discontinued due to Dose Limiting Toxicities (DLTs).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics (PK): Maximum Concentration (Cmax)</title>
        <time_frame>Prior to Infusion and Immediately Following End of Infusion (Cohorts 1 and 2) at 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 264 and 336 hours and (Cohorts 3 and 4) at 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 264, 336, 408 and 504 Hours Following End of Infusion</time_frame>
        <population>All participants who received at least 1 dose of study drug and had evaluable PK data for Cmax (First Dose and Fourth doses for Cohorts 1 and 2 and First and Third doses for Cohorts 3 and 4.)</population>
        <group_list>
          <group group_id="O1">
            <title>Cixutumumab Cohort 1</title>
            <description>6 mg/kg of cixutumumab was administered intravenously (IV) every 2 weeks for 6 weeks (one cycle).</description>
          </group>
          <group group_id="O2">
            <title>Cixutumumab Cohort 2</title>
            <description>10 mg/kg of cixutumumab was administered IV every 2 weeks for 6 weeks (one cycle).</description>
          </group>
          <group group_id="O3">
            <title>Cixutumumab Cohort 3</title>
            <description>15 mg/kg of cixutumumab was administered IV every 3 weeks for 6 weeks (one cycle).</description>
          </group>
          <group group_id="O4">
            <title>Cixutumumab Cohort 4</title>
            <description>20 mg/kg of cixutumumab was administered IV every 3 weeks for 6 weeks (one cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK): Maximum Concentration (Cmax)</title>
          <population>All participants who received at least 1 dose of study drug and had evaluable PK data for Cmax (First Dose and Fourth doses for Cohorts 1 and 2 and First and Third doses for Cohorts 3 and 4.)</population>
          <units>microgram/milliliter (μg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>First Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184" spread="34"/>
                    <measurement group_id="O2" value="643" spread="95"/>
                    <measurement group_id="O3" value="1020" spread="32"/>
                    <measurement group_id="O4" value="1390" spread="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fourth Dose or Third Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">The geometric mean and % coefficient of variation (CV) were not calculated because there was 1 evaluable participant. Cmax=390.019 μg/mL</measurement>
                    <measurement group_id="O2" value="734" spread="102"/>
                    <measurement group_id="O4" value="NA" spread="NA">The geometric mean and % CV were not calculated because there was 1 participant in Cohort 4. Cmax=1741.312 μg/mL</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK: Area Under the Curve From Zero to Infinity AUC(0-∞)</title>
        <time_frame>Prior to Infusion and Immediately Following End of Infusion (Cohorts 1 and 2) at 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 264 and 336 hours and (Cohorts 3 and 4) at 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 264, 336, 408 and 504 Hours Following End of Infusion</time_frame>
        <population>All participants who received at least 1 dose of study drug and had evaluable PK data for AUC(0-∞). First Dose for Cohorts 1, 2, 3, and 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Cixutumumab Cohort 1</title>
            <description>6 mg/kg of cixutumumab was administered intravenously (IV) every 2 weeks for 6 weeks (one cycle).</description>
          </group>
          <group group_id="O2">
            <title>Cixutumumab Cohort 2</title>
            <description>10 mg/kg of cixutumumab was administered IV every 2 weeks for 6 weeks (one cycle).</description>
          </group>
          <group group_id="O3">
            <title>Cixutumumab Cohort 3</title>
            <description>15 mg/kg of cixutumumab was administered IV every 3 weeks for 6 weeks (one cycle).</description>
          </group>
          <group group_id="O4">
            <title>Cixutumumab Cohort 4</title>
            <description>20 mg/kg of cixutumumab was administered IV every 3 weeks for 6 weeks (one cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>PK: Area Under the Curve From Zero to Infinity AUC(0-∞)</title>
          <population>All participants who received at least 1 dose of study drug and had evaluable PK data for AUC(0-∞). First Dose for Cohorts 1, 2, 3, and 4.</population>
          <units>micrograms•hour/milliliter (μg•h/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26500" spread="19"/>
                    <measurement group_id="O2" value="42000" spread="50"/>
                    <measurement group_id="O3" value="120000" spread="51"/>
                    <measurement group_id="O4" value="157000" spread="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serum Anti-Cixutumumab Antibody Assessment Immunogenicity</title>
        <description>No participants were analyzed for the development of circulating positive anti-cixutumumab antibodies due to no assay available.</description>
        <time_frame>6 months</time_frame>
        <population>No participants were analyzed due to no assay available.</population>
        <group_list>
          <group group_id="O1">
            <title>Cixutumumab Cohort 1</title>
            <description>6 mg/kg of cixutumumab was administered IV every 2 weeks for 6 weeks (one cycle).</description>
          </group>
          <group group_id="O2">
            <title>Cixutumumab Cohort 2</title>
            <description>10 mg/kg of cixutumumab was administered IV every 2 weeks for 6 weeks (one cycle).</description>
          </group>
          <group group_id="O3">
            <title>Cixutumumab Cohort 3</title>
            <description>15 mg/kg of cixutumumab was administered IV every 3 weeks for 6 weeks (one cycle).</description>
          </group>
          <group group_id="O4">
            <title>Cixutumumab Cohort 4</title>
            <description>20 mg/kg of cixutumumab was administered IV every 3 weeks for 6 weeks (one cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serum Anti-Cixutumumab Antibody Assessment Immunogenicity</title>
          <description>No participants were analyzed for the development of circulating positive anti-cixutumumab antibodies due to no assay available.</description>
          <population>No participants were analyzed due to no assay available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK: Area Under Concentration Versus Time Curve During One Dosing Interval (AUCtau)</title>
        <time_frame>Prior to Infusion and Immediately Following End of Infusion (Cohorts 1 and 2) at 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 264 and 336 hours and (Cohorts 3 and 4) at 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 264, 336, 408 and 504 Hours Following End of Infusion</time_frame>
        <population>All participants who received 1 dose of study drug and had evaluable PK data for (AUCtau). Fourth doses for Cohorts 1 and 2. No participant was evaluable in Cohorts 3 and 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Cixutumumab Cohort 1</title>
            <description>6 mg/kg of cixutumumab was administered IV every 2 weeks for 6 weeks (one cycle).</description>
          </group>
          <group group_id="O2">
            <title>Cixutumumab Cohort 2</title>
            <description>10 mg/kg of cixutumumab was administered IV every 2 weeks for 6 weeks (one cycle).</description>
          </group>
          <group group_id="O3">
            <title>Cixutumumab Cohort 3</title>
            <description>15 mg/kg of cixutumumab was administered IV every 3 weeks for 6 weeks (one cycle).</description>
          </group>
          <group group_id="O4">
            <title>Cixutumumab Cohort 4</title>
            <description>20 mg/kg of cixutumumab was administered IV every 3 weeks for 6 weeks (one cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>PK: Area Under Concentration Versus Time Curve During One Dosing Interval (AUCtau)</title>
          <population>All participants who received 1 dose of study drug and had evaluable PK data for (AUCtau). Fourth doses for Cohorts 1 and 2. No participant was evaluable in Cohorts 3 and 4.</population>
          <units>(μg•h/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36400" spread="8"/>
                    <measurement group_id="O2" value="63600" spread="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Half-life (t1/2)</title>
        <time_frame>Prior to Infusion and Immediately Following End of Infusion (Cohorts 1 and 2) at 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 264, and 336 hours and (Cohorts 3 and 4) at 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 264, 336, 408 and 504 hours) Following End of Infusion</time_frame>
        <population>All participants who received at least 1 dose of study drug and had evaluable PK data for t1/2 estimation (First Dose and Fourth doses for Cohorts 1 and 2 and First Dose and Third doses for Cohorts 3 and 4.)</population>
        <group_list>
          <group group_id="O1">
            <title>Cixutumumab Cohort 1</title>
            <description>6 mg/kg of cixutumumab was administered IV every 2 weeks for 6 weeks (one cycle).</description>
          </group>
          <group group_id="O2">
            <title>Cixutumumab Cohort 2</title>
            <description>10 mg/kg of cixutumumab was administered IV every 2 weeks for 6 weeks (one cycle).</description>
          </group>
          <group group_id="O3">
            <title>Cixutumumab Cohort 3</title>
            <description>15 mg/kg of cixutumumab was administered IV every 3 weeks for 6 weeks (one cycle).</description>
          </group>
          <group group_id="O4">
            <title>Cixutumumab Cohort 4</title>
            <description>20 mg/kg of cixutumumab was administered IV every 3 weeks for 6 weeks (one cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Half-life (t1/2)</title>
          <population>All participants who received at least 1 dose of study drug and had evaluable PK data for t1/2 estimation (First Dose and Fourth doses for Cohorts 1 and 2 and First Dose and Third doses for Cohorts 3 and 4.)</population>
          <units>day</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>First Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.08" lower_limit="5.29" upper_limit="6.88"/>
                    <measurement group_id="O2" value="4.06" lower_limit="3.33" upper_limit="6.04"/>
                    <measurement group_id="O3" value="9.88" lower_limit="6.58" upper_limit="16.0"/>
                    <measurement group_id="O4" value="8.83" lower_limit="4.67" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fourth Dose or Third Dose (n=2,2,1,0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">The geometric mean and range were not calculated because there were 2 participants in Cohort 1. t1/2 values = 5.50; 4.75 days.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">The geometric mean and range were not calculated because there were 2 participants in Cohort 2. t1/2 values = 4.29; 5.92 days.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">The geometric mean and full range was not calculated due to 1 evaluable participant in Cohort 3. t1/2 value=6.96 days</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])</title>
        <description>Response defined per Response Evaluation Criteria In Solid Tumors (RECIST 1.1) criteria: Complete Response (CR)=disappearance of all target lesions; Partial Response (PR)=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions.</description>
        <time_frame>From the First Dose up to 32 Months</time_frame>
        <population>All participants who received 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cixutumumab Cohort 1</title>
            <description>6 mg/kg of cixutumumab was administered IV every 2 weeks for 6 weeks (one cycle).</description>
          </group>
          <group group_id="O2">
            <title>Cixutumumab Cohort 2</title>
            <description>10 mg/kg of cixutumumab was administered IV every 2 weeks for 6 weeks (one cycle).</description>
          </group>
          <group group_id="O3">
            <title>Cixutumumab Cohort 3</title>
            <description>15 mg/kg of cixutumumab was administered IV every 3 weeks for 6 weeks (one cycle).</description>
          </group>
          <group group_id="O4">
            <title>Cixutumumab Cohort 4</title>
            <description>20 mg/kg of cixutumumab was administered IV every 3 weeks for 6 weeks (one cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])</title>
          <description>Response defined per Response Evaluation Criteria In Solid Tumors (RECIST 1.1) criteria: Complete Response (CR)=disappearance of all target lesions; Partial Response (PR)=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions.</description>
          <population>All participants who received 1 dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="41.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="70.8"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Drug Clearance (CL)</title>
        <time_frame>Prior to Infusion and Immediately Following End of Infusion (Cohorts 1 and 2) at 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 264, and 336 hours and (Cohorts 3 and 4) at 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 264, 336, 408 and 504 hours) Following End of Infusion</time_frame>
        <population>All participants who received at least 1 dose of study drug and had evaluable PK data for CL estimation (First Dose and Fourth doses for Cohorts 1 and 2 and First Dose and Third doses for Cohorts 3 and 4.)</population>
        <group_list>
          <group group_id="O1">
            <title>Cixutumumab Cohort 1</title>
            <description>6 mg/kg of cixutumumab was administered IV every 2 weeks for 6 weeks (one cycle).</description>
          </group>
          <group group_id="O2">
            <title>Cixutumumab Cohort 2</title>
            <description>10 mg/kg of cixutumumab was administered IV every 2 weeks for 6 weeks (one cycle).</description>
          </group>
          <group group_id="O3">
            <title>Cixutumumab Cohort 3</title>
            <description>15 mg/kg of cixutumumab was administered IV every 3 weeks for 6 weeks (one cycle).</description>
          </group>
          <group group_id="O4">
            <title>Cixutumumab Cohort 4</title>
            <description>20 mg/kg of cixutumumab was administered IV every 3 weeks for 6 weeks (one cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Drug Clearance (CL)</title>
          <population>All participants who received at least 1 dose of study drug and had evaluable PK data for CL estimation (First Dose and Fourth doses for Cohorts 1 and 2 and First Dose and Third doses for Cohorts 3 and 4.)</population>
          <units>Liter/hour (L/h)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>First Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0137" spread="13"/>
                    <measurement group_id="O2" value="0.0135" spread="53"/>
                    <measurement group_id="O3" value="NA" spread="NA">The geometric mean and CV were not calculated due to 2 participants in Cohort 3. Values=0.00574; 0.00948 L/h</measurement>
                    <measurement group_id="O4" value="0.00709" spread="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fourth Dose or Third Dose (n=2,3,0,0)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">The geometric mean and CV were not calculated due to 2 participants in Cohort 1. Values=0.0124; 0.0118 L/h</measurement>
                    <measurement group_id="O2" value="0.00994" spread="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>All participants who received at least 1 dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cixutumumab Cohort 1</title>
          <description>6 mg/kg of cixutumumab was administered IV every 2 weeks for 6 weeks (one cycle).</description>
        </group>
        <group group_id="E2">
          <title>Cixutumumab Cohort 2</title>
          <description>10 mg/kg of cixutumumab was administered IV every 2 weeks for 6 weeks (one cycle).</description>
        </group>
        <group group_id="E3">
          <title>Cixutumumab Cohort 3</title>
          <description>15 mg/kg of cixutumumab was administered IV every 3 weeks for 6 weeks (one cycle).</description>
        </group>
        <group group_id="E4">
          <title>Cixutumumab Cohort 4</title>
          <description>20 mg/kg of cixutumumab was administered IV every 3 weeks for 6 weeks (one cycle).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Movement disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Inner ear disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Injection site extravasation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood amylase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Glycosylated haemoglobin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="8" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Glucose tolerance impaired</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Onychalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

